CO2PD: Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05704881
Collaborator
Hospices Civils de Lyon (Other)
240
2
34
120
3.5

Study Details

Study Description

Brief Summary

Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: End-Tidal CO2 measurement during COPD exacerbation

Detailed Description

The study will be conducted in the emergency departments of Grenoble and Lyon University Hospitals.

Patients will be recruited by the dispatch nurse at the emergency department reception according to the inclusion and non-inclusion criteria. The EtCO2 will be measured at the emergency reception during assessment of vital signs by the same nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. Once the patient is discharged from the emergency department, the primary and secondary endpoints will be collected by a clinical research associate 24 hours after admission from medical record.

Study Design

Study Type:
Observational
Anticipated Enrollment :
240 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Monitoring of the End-tidal Carbon Dioxide (EtCO2 ) as a Severity Criterion in COPD Exacerbations: a Prospective Observational Study
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease

Patient admitted for acute Exacerbation of COPD. The measurement of EtCO2 will be performed at the emergency department

Diagnostic Test: End-Tidal CO2 measurement during COPD exacerbation
The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.

Outcome Measures

Primary Outcome Measures

  1. Invasive or non-invasive ventilation (NIV) use (hour/min) [24 hours]

    Invasive or non-invasive ventilation (NIV) use (hour/min)

Secondary Outcome Measures

  1. Arterial Blood Gaz measurement [15 minutes (after emergency admission)]

    PaCO2 and pH values

  2. Concordance between EtCO2 (mmHg) and PaCO2 (mmHg) using Bland and Altman graphical method. [15 minutes (after emergency admission)]

    A Bland and Altman graph will be used to estimate the concordance between values of EtCO2 (mmHg) and PaCO2 (mmHg) measured on the first blood gases sample performed in the emergency department.

  3. Concordance between EtCO2 (mmHg) and PvCO2 (mmHg) using Bland and Altman graphical method. [15 minutes (after emergency admission)]

    A Bland and Altman graph will be used to estimate the concordance between values of EtCO2 (mmHg) and PvCO2 (mmHg) measured on the first venous blood sample performed in the emergency department.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and/or family

  • Male or female≥18 years old who did not oppose to participating in the study

Exclusion Criteria:
  • Hypotension (SBP < 90 mmHg or MBP < 65 mmHg)

  • Patient already included in the study during a previous visit to the emergency department

  • Patient already ventilated with invasive or NIV during admission to the emergency department

  • COPD exacerbation rejected after medical and additional examinations

  • Non-communicative or non-French speaking patients, or with impaired comprehension, or with impaired consciousness

  • Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Grenoble Alpes Grenoble Isère France 38000
2 Hospices Civils de Lyon Lyon Rhône France 69000

Sponsors and Collaborators

  • University Hospital, Grenoble
  • Hospices Civils de Lyon

Investigators

  • Study Director: Damien VIGLINO, Prof. MD PhD, University Hospital, Grenoble
  • Principal Investigator: Nicolas SEGOND, MD, University Hospital, Grenoble

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT05704881
Other Study ID Numbers:
  • 38RC22.077
  • 2022-A02330-43
First Posted:
Jan 30, 2023
Last Update Posted:
Jan 30, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Grenoble
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2023